PIPilar Iranzo

Pilar Iranzo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pilar Iranzo has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Case Report of Concurrent Pyostomatitis Vegetans-Like/Intercellular Immunoglobulin A Dermatosis and Uveitic Macular Edema Reacting Exclusively with Desmocollins: A Possible Common Pathogenesis

    by Xavier Bosch-Amate, Pilar Iranzo-Fernández, José Manuel Mascaró, Norito Ishii, Takashi Hashimoto

    Bosch-Amate X, et al. Ann Dermatol. 2023 Mar;35:e29. https://doi.org/10.5021/ad.20.299

  • Open Access

    Excelente respuesta clínica a largo plazo con rivaroxabán en vasculopatía livedoide. Un estudio retrospectivo

    by D. Morgado-Carrasco, J. Ibaceta, P. Iranzo, X. Bosch-Amate, J.M. Mascaró-Galy


  • Childhood Vulvar Mucous Membrane Pemphigoid,

    by Ignasi Marti-Marti, Daniel Rizo-Potau, Sara Gómez, Helena Pallarès, Pilar Iranzo


  • Oral Lichenoid Lesions Associated With Mediastinal Mass and Hypogammaglobulinemia in a Middle-aged Man

    by Mar Luque-Luna, Francesc Alamon-Reig, Pilar Iranzo

    Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.

  • Oral lichenoid lesions as a sign of Good’s syndrome

    by Mar Luque‐Luna, Francesc Alamon‐Reig, Pilar Iranzo‐Fernández


  • Open Access

    High-Frequency Ultrasound to Assess Activity in Connective Tissue Panniculitis

    by Priscila Giavedoni, Sebastian Podlipnik, Irene Fuertes de Vega, Pilar Iranzo, José Manuel Mascaró

    Determining disease activity from clinical signs in patients with connective tissue panniculitis (CTP) is often challenging but is essential for therapeutic decision making, which largely relies on immunosuppressant treatment. High-frequency ultrasound (HFUS) may be useful in supporting such decisions by accurately determining CTP activity. This study aimed to investigate the accuracy of HFUS in identifying signs of CTP activity or inactivity and assess its usefulness in therapeutic decision making. A prospective cohort study of consecutive patients with biopsy-proven CTP receiving HFUS was conducted in a tertiary university hospital (2016–2020). HFUS was performed at inclusion and at each 3- or 6-month follow-up visit, depending on disease activity. Twenty-three patients with CTP were included, and 134 HFUSs were performed. In 59.7% (80) of the evaluations, the clinical presentation did not show whether CTP was active or not. In these cases, HFUS showed activity in 38.7% (31) and inactivity in 61.3% (49). In 71.25% (57) of the visits, HFUS was the determinant for therapeutic decisions. Further follow-up showed consistent clinical and HFUS responses in all unclear cases after treatment modification. HFUS appears to be a useful adjunct to the clinical examination for CTP to assess activity and make therapeutic decisions.


  • Open Access

    Anti-Desmocollin Autoantibodies in Autoimmune Blistering Diseases

    by Xavier Bosch-Amate, Pilar Iranzo, Marta Ivars, José Manuel Mascaró Galy, Agustín España

    The presence of anti-desmocollin (Dsc) antibodies is rarely described in autoimmune blistering diseases patients. Moreover, several clinical phenotypes of pemphigus may be associated with these antibodies. In this review we analyze clinicopathological, immunologic and outcome features of anti-Dsc autoimmune blistering diseases patients, to improve their diagnosis and management. We conducted a systematic search of PubMed and Embase (1990-present) for studies reporting cases of autoimmune blistering diseases with anti-Dsc antibodies. We classified the selected patients as patients with exclusively anti-Dsc autoantibodies, and patients with anti-Dsc and other autoantibodies. Of 93 cases with anti-Dsc autoantibodies included, 38 (41%) had exclusively these antibodies. Only 18% of patients presented with the typical clinicopathological phenotype of pemphigus vulgaris or pemphigus foliaceous. Mucosal involvement was seen in approximately half of the patients. Up to 18% of cases were associated with neoplasms. Acantholysis was described in 54% of cases with histopathological information. Treatments and outcomes vary in the different clinical phenotypes. The presence of anti-Dsc antibodies must be suspected mainly in those patients with either atypical pemphigus, in special with clinical pustules, or in cases showing intraepithelial or dermal neutrophilic/eosinophilic infiltrate on histological examination and dual pattern by direct immunofluorescence examination.


  • Open Access

    A facility and community-based assessment of scabies in rural Malawi

    by Cristina Galván-Casas, Oriol Mitjá, Sara Esteban, Jacob Kafulafula, Texon Phiri, Íñigo Navarro-Fernández, Concepción Román-Curto, Hassani Mtenje, Gerald Thauzeni, Elizabeth Harawa, et al.

    Background: Scabies is a neglected tropical disease of the skin, causing severe itching, stigmatizing skin lesions and systemic complications. Since 2015, the DerMalawi project provide an integrated skin diseases clinics and Tele-dermatology care in Malawi. Clinic based data suggested a progressive increase in scabies cases observed. To better identify and treat individuals with scabies in the region, we shifted from a clinic-based model to a community based outreach programme. Methodology/Principal findings: From May 2015, DerMalawi project provide integrated skin diseases and Tele-dermatological care in the Nkhotakota and Salima health districts in Malawi. Demographic and clinical data of all patients personally attended are recorded. Due to a progressive increase in the number of cases of scabies the project shifted to a community-based outreach programme. For the community outreach activities, we conducted three visits between 2018 to 2019 and undertook screening in schools and villages of Alinafe Hospital catchment area. Treatment was offered for all the cases and school or household contacts. Scabies increased from 2.9% to 39.2% of all cases seen by the DerMalawi project at clinics between 2015 to 2018. During the community-based activities approximately 50% of the population was assessed in each of three visits. The prevalence of scabies was similar in the first two rounds, 15.4% (2392) at the first visit and 17.2% at the second visit. The prevalence of scabies appeared to be lower (2.4%) at the third visit. The prevalence of impetigo appeared unchanged and was 6.7% at the first visit and 5.2% at the final visit. Conclusions/Significance: Prevalence of scabies in our setting was very high suggesting that scabies is a major public health problem in parts of Malawi. Further work is required to more accurately assess the burden of disease and develop appropriate public health strategies for its control.


  • Subcutaneous rituximab for autoimmune bullous diseases

    by C. Riquelme‐Mc Loughlin, P. Iranzo

    Rituximab, a monoclonal antibody targeting the CD-20 molecule, was originally manufactured as an intravenous infusion (IV). In addition, a subcutaneous (SC) formulation has been produced with a recombinant hyaluronidase that creates an area in which a concentrated and fixed dose of rituximab can be injected (or infused using a syringe pump), into the subcutaneous tissue. SC rituximab is produced in vials of 1,400 and 1,600 mg. Per standard practice, patients receive 375 or 500 mg/m2 IV rituximab in the first cycle, so that administration can be modified in the event of adverse reactions, followed by 1,400 or 1,600 mg respectively of the SC administration in the forthcoming cycles.


  • Oral whitish lichenoid lesions after treatment with intravenous immunoglobulins

    by Sandra Valenzuela‐Ubiña, Pilar Iranzo‐Fernandez

    Click on the article title to read more.